⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14624334 | 1.00 | — | — | |
| SCHEMBL22317546 | 1.00 | — | — | |
| SCHEMBL21123603 | 1.00 | — | — | |
| SCHEMBL26253255 | 1.00 | — | — | |
| SCHEMBL14537230 | 1.00 | — | — | |
| SCHEMBL14537126 | 0.93 | — | — | |
| SCHEMBL26652142 | 0.88 | FGF1 (0.31) | — | |
| SCHEMBL767695 | 0.86 | — | — | |
| SCHEMBL13222901 | 0.85 | FGF1 (0.33) | — | |
| SCHEMBL12253802 | 0.85 | FGF1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11802283-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230212575-A1 | Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency | INTELLIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20180216111-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |
| US-9566293-B2 | Oral delivery of therapeutically effective LNA oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-02-14 | — | — | US | disclosed |
| US-9364495-B2 | Oral delivery of therapeutically effective LNA oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2016-06-14 | — | — | US | disclosed |
| US-20160032289-A1 | Oral Delivery of Therapeutically Effective LNA Oligonucleotides | SANTARIS PHARMA A/S (DK) | 2016-02-04 | — | — | US | disclosed |
| US-20120322851-A1 | ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2012-12-20 | — | — | US | disclosed |